Top

Published in:

2018 | OriginalPaper | Chapter

Nanotechnology in Ophthalmology

Authors : Nenad Petrovic, Mirjana Janicijevic Petrovic, Suncica Sreckovic, Svetlana Jovanovic, Dusan Todorovic, Tatjana Sarenac Vulovic

Published in: Commercialization of Nanotechnologies–A Case Study Approach

Publisher: Springer International Publishing

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Nanotechnology has already been used for the purpose of the measurement as well as treatment of great number of ophthalmological diseases. The applications of Nanotechnology to Ophthalmology refer to the following: delivery of drugs, peptides and genes, biomedical imaging and diagnostics of distinct disorders of the eye, study of pathogenesis of the eye disease. Regenerative nanomedicine is considered to be a prospective approach for treating retinal degenerations and the second cranial nerve regeneration. Our manuscript included possible different application for ophthalmological drug using nanotechnology. Also, we described the importance of nanotechnology for imaging, diagnostic and monitoring of ocular diseases. Nanobiotechnology for glaucoma treatment, as well as nanoparticles for gene delivery therapy of retinal degenerative disease, is most attractive approach for the ophthalmological treatment.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

previous chapter Characteristics and Applications of Silver Nanoparticles

next chapter Ever-Expanding Application Potentials for Iron-Based Nanomaterials: Catalyses and Biomedicine

Alonso MJ, Sánchez A (2003) The potential of chitosan in ocular drug delivery. J Pharm Pharmacol 55:1451–1463CrossRef

Badawi AA, El-Laithy HM, El Qidra RK et al (2008) Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res 31:1040–1049CrossRef

Bayens R, Gurny R (1997) Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv 72:191–202CrossRef

Beeley NR, Rossi JV, Mello-Filho PA et al (2005) Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J Biomed Mater Res A 73:437–444CrossRef

Bejjani R, BenEzra D, Cohen H et al (2005) Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 11:124–132

Bejjani RA, Andrieu C, Bloquel C et al (2007) Electrically assisted ocular gene therapy. Surv Ophthalmol 52(2):196–208CrossRef

Bhisitkul RB, Keller CG (2005) Development of microelectromechanical systems (MEMS) forceps for intraocular surgery. Br J Ophthalmol 89:1586–1588CrossRef

Bloquel C, Bourges JL, Touchard E et al (2006) Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev 58:1224–1242CrossRef

Bourges JL, Gautier SE, Delie F et al (2003a) Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 44:3562–3569CrossRef

Bourges JL, Bloquel C, Thomas A et al (2003b) Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 58(11):1182–1202CrossRef

Bondì ML, Craparo EF, Giammona G et al (2007) Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv 14:61–67CrossRef

Bourlais CL, Acar L, Zia H et al (1998) Ophthalmic drug delivery systems—recent advances. Prog Retin Eye Res 17(1):33–58CrossRef

Bucolo C, Maltese A, Drago F (2008) When nanotechnology meets the ocular surface. Expert Rev Ophthalmol 3:325–332CrossRef

Cai X, Conley S, Naash M (2008) Nanoparticle applications in ocular gene therapy. Vision Res 48:319–324CrossRef

Cai X, Nash Z, Conley SM et al (2009) A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS ONE 4:e5290CrossRef

Chu TC, He Q, Potter DE (2002) Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent. J Ocul Pharmacol Ther 18:507–514CrossRef

Cohen-Karni T, Timko BP, Weiss LE et al (2009) Flexible electrical recording from cells using nanowire transistor arrays. Proc Natl Acad Sci USA 106:7309–7313CrossRef

Dal Pizzol C, O’Reilly A, Winter E et al (2016) Application of response surface methodology for the technological improvement of solid lipid nanoparticles. J Nanosci Nanotechnol 16(2):47–1238

De Campos AM, Diebold Y, Carvalho EL et al (2004) Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 21:803–810CrossRef

De Campos AM, Sanchez A, Alonso MJ (2001) Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 224:159–168CrossRef

De Kozak Y, Andrieux K, Villarroya H et al (2004) Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 34:12–3702CrossRef

Del Amo EM, Urtti A (2008) Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 13:135–143CrossRef

De la Fuente M, Csaba N, Garcia-Fuentes M et al (2008a) Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomed 3:845–857CrossRef

De la Fuente M, Seijo B, Alonso MJ (2008b) Novel hyaluronan-based nanocarriers for transmucosal delivery of macromolecules. Macromol Biosci 8:441–450CrossRef

Diebold Y, Calonge M (2010) Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596–609CrossRef

Diebold Y, Jarrín M, Sáez V et al (2007) Ocular drug delivery by liposomeechitosan nanoparticle complexes (LCS-NP). Biomaterials 28:1553–1564CrossRef

Ding XQ, Quiambao AB, Fitzgerald JB et al (2009) Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS ONE 4:e7410CrossRef

Dobrovolskaia MA, McNeil SE (2007) Immunological properties of engineered nanomaterials. Nat Nanotechnol 2:469–478CrossRef

Dresher RP, Irazoqui PP (2007) A compact nanopower low output impedance CMOS operational amplifier for wireless intraocular pressure recordings. Conf Proc IEEE Eng Med Biol Soc 2007:6056–6059

Dugan LL, Turetsky DM, Du C et al (1997) Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 94:9434–9439CrossRef

Dugan LL, Lovett EG, Quick KL et al (2001) Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 7:243–246CrossRef

Edwards A, Prausnitz MR (2001) Predicted permeability of the cornea to topical drugs. Pharm Res 18:1497–1508CrossRef

Elbary AA, Kassem MA, Abou Samra MM et al (2008) Formulation and hypoglycemic activity of pioglitazone-cyclodextrin inclusion complexes. Drug Discov Ther 2(2):94–107

Ellis-Behnke RG, Liang YX, You SW et al (2006) Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA 103:5054–5059CrossRef

Farjo R, Skaggs J, Quiambao AB (2006) Efficient nonviral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 1:e38CrossRef

Farjo R, Skaggs J, Quiambao AB et al (2007) Effect of Rds abundance on cone outer segment morphogenesis, photoreceptor gene expression, and outer limiting membrane integrity. J Comp Neurol 504(6):30–619CrossRef

Ferreira L, Karp JM, Nobre L et al (2008a) New opportunities: the use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell 3:136–146CrossRef

Ferreira L, Squier T, Park H et al (2008b) Human embryoid bodies containing nano- and microparticulate delivery vehicles. Adv Mater 20:2285–2291CrossRef

Fresta M, Panico AM, Bucolo C et al (1999) Characterization and in-vivo ocular absorption of liposome encapsulated acyclovir. J Pharm Pharmacol 51:565–576CrossRef

Fresta M, Fontana G, Bucolo C et al (2001) Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. J Pharm Sci 90(3):97–288CrossRef

Garhwal R, Shady SF, Ellis EJ et al (2012) Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials. Invest Ophthalmol Vis Sci 53:1341–1352CrossRef

Gref R, Minamitake Y, Peracchia MT et al (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603CrossRef

Gulsen D, Chauhan A (2005) Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. Int J Pharm 292:95–117CrossRef

Gurunathan S, Lee KJ, Kalishwaralal K et al (2009) Antiangiogenic properties of silver nanoparticles. Biomaterials 30:6341–6350CrossRef

Hahn U, Gorka M, Vogtle F et al (2002) Light-harvesting dendrimers: efficient intra- and intermolecular energy-transfer processes in a species containing 65 chromophoric groups of four different types. Angew Chem Int Ed Engl 41(3595–3598):3514

Hayashi A, Naseri A, Pennesi ME et al (2009) Subretinal delivery of immunoglobulin G with gold nanoparticles in the rabbit eye. Jpn J Ophthalmol 53:249–256CrossRef

Helmchen F, Denk W (2005) Deep tissue two-photon microscopy. Nat Methods 2:932–940CrossRef

Hsiue GH, Hsu SH, Yang CC et al (2002) Preparation of controlled release ophthalmic drops, for glaucoma therapy using thermosensitive poly-N-isopropylacrylamide. Biomaterials 23:457–462CrossRef

Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673–687CrossRef

Ideta R, Tasaka F, Jang WD et al (2005) Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer. Nano Lett 5:2426–2431CrossRef

Irache JM, Merodio M, Arnedo A et al (2005) Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem 5:293–305CrossRef

Jani PD, Singh N, Jenkins C et al (2007) Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 48:2030–2036CrossRef

Jarvinen K, Jarvinen T, Urtti A (1995) Ocular absorption following topical delivery. Adv Drug Deliv Rev 16:3–19CrossRef

Jiang C, Moore MJ, Zhang X et al (2007) Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis 13:1783–1792

Johnson LN, Cashman SM, Kumar-Singh R (2008) Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol Ther 16:14–107CrossRef

Juberías JR, Calonge M, Gómez S et al (1998) Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection model in the rat. Curr Eye Res 17:39–46CrossRef

Kachi S, Oshima Y, Esumi N et al (2005) Nonviral ocular gene transfer. Gene Ther 12:843–851CrossRef

Kao HJ, Lin HR, Lo YL et al (2006) Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. J Pharmacokinet Pharmacodyn 58:179–186

Kassem MA, Abdel Rahman AA, Ghorab MM et al (2007) Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340:126–133CrossRef

Kayser O, Lemke A, Hernandez-Trejo N (2005) The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 6:3–5CrossRef

Keister JC, Cooper ER, Missel PJ et al (1991) Limits on optimizing ocular drug delivery. J Pharm Sci 80:50–53CrossRef

Kim JH, Kim JH, Kim KW et al (2009) Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 20:505101CrossRef

Kim P, Lieber CM (1999) Nanotube nanotweezers. Science 286:2148–2150CrossRef

Komeima K, Rogers BS, Campochiaro PA (2007) Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 213:809–815CrossRef

Li H, Tran VV, Hu Y et al (2006) A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp Eye Res 83:33–824

Li VH, Wood RW, Kreuter J et al (1986) Ocular drug delivery of progesterone using nanoparticles. J Microencapsul 3:213–218CrossRef

Losa C, Marchal-Heussler L, Orallo F (1993) Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res 10:80–87CrossRef

Mannermaa E, Vellonen KS, Urtti A (2006) Drugtransport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 58:1136–1163CrossRef

Marano RJ, Toth I, Wimmer N et al (2005) Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 12:1544–1550CrossRef

Merodio M, Arnedo A, Renedo MJ et al (2001) Ganciclovir-loaded nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci 12:251–259CrossRef

Merodio M, Espuelas MS, Mirshahi M et al (2002) Efficacy of ganciclovir-loaded nanoparticles in human cytomegalovirus (HCMV)-infected cells. J Drug Target 10:231–238CrossRef

Mo Y, Barnett ME, Takemoto D et al (2007) Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis 13:746–757

Motwani SK, Chopra S, Talegaonkar S et al (2008) Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 68:513–525

Neeley WL, Redenti S, Klassen H et al (2008) A microfabricated scaffold for retinal progenitor cell grafting. Biomaterials 29:418–426CrossRef

Normand N, Valamanesh F, Savoldelli M (2005) VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Mol Vis 11:184–191

Nygaard UC, Hansen JS, Samuelsen M et al (2009) Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice. Toxicol Sci 109:113–123CrossRef

Paasonen L, Laaksonen T, Johans C et al (2007) Gold nanoparticles enable selective light-induced contents release from liposomes. J Control Release 122:86–93CrossRef

Pan T, Brown JD, Ziaie B (2006) An artificial nano-drainage implant (ANDI) for glaucoma treatment. Conf Proc IEEE Eng Med Biol Soc 1:3174–3177

Panessa-Warren BJ, Maye MM, Warren JB et al (2009) Single walled carbon nanotube reactivity and cytotoxicity following extended aqueous exposure. Environ Pollut 157:1140–1151CrossRef

Paolicelli P, de la Fuente M, Sánchez A et al (2009) Chitosan nanoparticles for drug delivery to the eye. Expert Opin Drug Deliv 6:239–253CrossRef

Park K, Chen Y, Hu Y et al (2009) Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularisation and diabetes-induced retinal vascular leakage. Diabetes 58:1902–1913CrossRef

Pignatello R, Bucolo C, Ferrara P et al (2002) Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16:53–61CrossRef

Pot SA, Liliensiek SJ, Myrna KE et al (2010) Nanoscale topography-induced modulation of fundamental cell behaviors of rabbit corneal keratocytes, fibroblasts, and myofibroblasts. Invest Ophthalmol Vis Sci 51:1373CrossRef

Prow TW (2010) Toxicity of nanomaterials to the eye. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:317–333CrossRef

Prow TW, Bhutto I, Grebe R et al (2008) Nanoparticle-delivered biosensor for reactive oxygen species in diabetes. Vision Res 48:478–485CrossRef

Prow T, Grebe R, Merges C et al (2006a) Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol Vis 12:616–625

Prow T, Smith JN, Grebe R et al (2006b) Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol Vis 12:606–615

Raju HB, Goldberg JL (2008) Nanotechnology for ocular therapeutics and tissue repair. Expert Rev Ophthalmol 3:431–436CrossRef

Reimer P, Ferucarbotran Balzer T (2003) (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276

Sakai T, Kuno N, Takamatsu F et al (2007) Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in Royal College of Surgeons rats. Invest Ophthalmol Vis Sci 48:3381–3387CrossRef

Sakai T, Kohno H, Ishihara T et al (2006) Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res 82:657–662CrossRef

Sanchez A, Alonso MJ (2006) Nanoparticular carriers for ocular drug delivery. In: Torchilin VP (ed) Nanoparticulates as drug carriers. Imperial College Press, London, UK, pp 649–673

Sasaki H, Yamamura K, Mukai T et al (1999) Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst 16:85–146CrossRef

Schoenwald RD (1990) Ocular drug delivery: pharmacokinetic considerations. Clin Pharmacokinet 18:255–269CrossRef

Shaunak S, Thomas S, Gianasi E et al (2004) Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 22:977–984CrossRef

Shen JK, Dong A, Hackett SF et al (2007) Oxidative damage in age-related macular degeneration. Histol Histopathol 22:1301–1308

Snyder RO (1999) Adeno-associated virus-mediated gene delivery. J Gene Med 1:166–175CrossRef

Sundback CA, Shyu JY, Wang Y et al (2005) Biocompatibility analysis of poly(glycerol sebacate) as a nerve guide material. Biomaterials 26:5454–5464CrossRef

Szebeni J, Alving CR, Rosivall L et al (2007) Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res 17:107–117CrossRef

Takeda A, Baffi JZ, Kleinman ME et al (2009) CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460:225–230CrossRef

Tao S, Young C, Redenti S et al (2007) Survival, migration and differentiation of retinal progenitor cells transplanted on micro-machined poly(methyl methacrylate) scaffolds to the subretinal space. Lab Chip 7:695–701CrossRef

Tomalia DA, Reyna LA, Svenson S (2007) Dendrimers as multipurpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 35:61–67

Toyama T, Matsuda H, Ishida I et al (2008) A case of toxic epidermal necrolysis-like dermatitis evolving from contact dermatitis of the hands associated with exposure to dendrimers. Contact Dermatitis 59:122–123CrossRef

Turturro S, Sunoqrot S, Ying H et al (2013) Sustained release of matrix metalloproteinase-3 to trabecular meshwork cells using biodegradable PLGA microparticles. Mol Pharm 10:32–3023CrossRef

Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Revs 58:1131–1135CrossRef

Vandamme TF, Brobeck L (2005) Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 102:23–38CrossRef

Vandervoort J, Ludwig A (2007) Ocular drug delivery: nanomedicine applications. Nanomed 2:11–21CrossRef

Vega E, Egea MA, Valls O et al (2006) Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J Pharm Sci 95:2393–2405CrossRef

Yenice I, Mocan MC, Palaska E et al (2008) Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp Eye Res 87:162–167CrossRef

Wadhawa S, Paliwal R, Paliwal SR et al (2010) Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target 18:292–302CrossRef

Wei C, Nagai T, Wei W et al (2007) New advances in nanomedicine: diagnosis and preventive medicine. Med Clin North Am 91:871–879CrossRef

Yamamoto S, Manabe N, Fujioka K et al (2007) Visualizing vitreous using quantum dots as imaging agents. IEEE Trans Nanobioscience 6:94–98CrossRef

Yanagisawa R, Takano H, Inoue KI et al (2009) Titanium dioxide nanoparticles aggravate atopic dermatitis-like skin lesions in NC/NGA mice. Exp Biol Med (Maywood) 234:314–322CrossRef

Yanagisawa R, Takano H, Inoue KI et al (2010) Size effects of polystyrene nanoparticles on atopic dermatitis-like skin lesions in NC/NGA mice. Int J Immunopathol Pharmacol 23:131–141CrossRef

Yoo SM, Kang M, Kang T et al (2013) Electrotriggered, spatioselective, quantitative gene delivery into a single cell nucleus by Au nanowire nanoinjector. Nano Lett 13(6):2431–2435CrossRef

Yorek MA (2003) The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res 37:471–480CrossRef

Yuan XB, Yuan YB, Jiang W et al (2008) Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 349:241–248CrossRef

Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598–614CrossRef

Zimmer A, Mutschler E, Lambrecht G et al (1994) Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery-system. Pharm Res 11:1435–1442CrossRef

Zolnik BS, González-Fernández A, Sadrieh N et al (2010) Minireview: nanoparticles and the immune system. Endocrinology 151:458–465CrossRef

Title: Nanotechnology in Ophthalmology
Authors: Nenad Petrovic
Mirjana Janicijevic Petrovic
Suncica Sreckovic
Svetlana Jovanovic
Dusan Todorovic
Tatjana Sarenac Vulovic
Publisher: Springer International Publishing
Book: Commercialization of Nanotechnologies–A Case Study Approach
Print ISBN: 978-3-319-56978-9

Electronic ISBN: 978-3-319-56979-6

Copyright Year: 2018
DOI: https://doi.org/10.1007/978-3-319-56979-6_11